Overview of China's booming biotech, from a brain implant to drug discovery
This Science Friday episode examines two major signs of China’s accelerating biotech ambitions: the country’s first approval of an invasive brain-computer interface (BCI) beyond clinical trials, and the rapid rise of its pharmaceutical and drug-discovery sector. Host Ira Flatow speaks with Wired staff writer Emily Mullen about BCIs, then with Georgetown University professor Dr. Siyun Kang about why China has become a major force in early-stage drug development.
Brain-Computer Interfaces: China’s NEO Approval
Why this matters
China recently became the first country to approve an invasive BCI for use outside clinical trials, a notable milestone that suggests the technology is becoming commercially viable and that China is now competitive with the U.S. in this field.
What the NEO implant does
- The implant, called NEO, is designed for people with limb paralysis caused by spinal cord injury.
- It does not go directly into brain tissue; instead, it sits on top of the dura mater.
- It works with a soft robotic glove to help restore hand-gripping function.
- The system was tested in trials with about three dozen people and is now being integrated into China’s health system.
How it compares with U.S. BCIs
- Neuralink: uses thin electrode threads inserted into brain tissue.
- Synchron: uses a stent-like device placed through a blood vessel so it rests against the brain.
- The episode emphasizes that BCIs are being developed in several different forms depending on intended use and implant strategy.
Real-world challenges
A major open question is whether these devices can work independently in everyday life:
- Many BCIs require frequent calibration.
- Some users still depend on field engineers or technical support.
- A key test for the industry will be whether these systems can truly restore independence, not just perform well in trials.
China’s Biotech Boom and Drug Discovery Surge
The big picture
China’s biotech industry is no longer just about manufacturing:
- Roughly 8% of new drug molecules were discovered in China a decade ago.
- Today, that figure is over 40%.
- China now conducts more clinical trials than the U.S. or Europe.
Why the industry is growing
Dr. Kang argues the rise is the result of more than a decade of coordinated investment in:
- science and research
- regulation
- clinical trial infrastructure
- biotech industry development
What changed in global pharma
Big pharmaceutical companies no longer rely only on in-house discovery. They increasingly:
- search for promising early-stage candidates globally
- outsource or license from biotech hubs in China, Singapore, and South Korea
- look for speed, efficiency, and lower cost
Why China is attractive for early-stage development
Chinese biotech firms are especially strong in:
- drug discovery
- preclinical research
- Phase 1 and Phase 2 trials
The reasons include:
- lower costs
- faster patient recruitment
- a more favorable regulatory environment
- efficient clinical trial infrastructure
The Strategic and Geopolitical Stakes
Major industry implications
The episode highlights a growing concern: China may increasingly own more of the pharmaceutical pipeline, from:
- discovery
- development
- manufacturing
- commercialization
That could reshape the global pharma industry and potentially reduce U.S. dominance in innovation and talent development.
Talent retention and ecosystem shift
Historically, top scientists often came to the U.S. for training and stayed there. Now:
- China has built the capacity to retain talent
- it can also train the next generation
- this may weaken the U.S. talent pipeline over time
Policy tensions
There are ongoing debates in the U.S. about:
- restricting some licensing deals
- limiting investment into Chinese biotech
- balancing national security concerns with scientific collaboration
Dr. Kang cautions that broad bans could harm patients by disrupting access to needed treatments.
What to Watch Next
In brain-computer interfaces
- Whether China approves more BCIs soon
- Whether U.S. firms like Neuralink and Synchron can scale into larger trials
- Whether BCIs can become truly easy for patients to use on their own
In biotech and pharma
- Whether more drugs are developed end-to-end in China
- Whether U.S. firms continue sourcing from Chinese startups
- Whether regulators in the U.S. and China harmonize standards or move toward deeper competition
Closing Note
The episode ends with a listener call for stories about AI in the doctor’s office, asking whether doctors or patients have experience with tools like OpenEvidence and similar systems.